Trexquant Investment LP Has $5.44 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

Trexquant Investment LP boosted its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 52.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 439,352 shares of the company's stock after buying an additional 150,538 shares during the quarter. Trexquant Investment LP owned about 0.29% of Wave Life Sciences worth $5,435,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of WVE. Charles Schwab Investment Management Inc. increased its stake in shares of Wave Life Sciences by 209.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company's stock worth $6,926,000 after purchasing an additional 571,345 shares during the period. FMR LLC raised its stake in shares of Wave Life Sciences by 174.5% in the third quarter. FMR LLC now owns 1,540,190 shares of the company's stock valued at $12,630,000 after purchasing an additional 979,110 shares in the last quarter. Barclays PLC boosted its stake in Wave Life Sciences by 171.1% during the third quarter. Barclays PLC now owns 159,241 shares of the company's stock worth $1,307,000 after buying an additional 100,498 shares in the last quarter. Geode Capital Management LLC boosted its stake in Wave Life Sciences by 14.3% during the third quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company's stock worth $18,615,000 after buying an additional 283,419 shares in the last quarter. Finally, State Street Corp increased its holdings in Wave Life Sciences by 2.6% in the 3rd quarter. State Street Corp now owns 2,321,248 shares of the company's stock valued at $19,034,000 after buying an additional 57,822 shares during the period. 89.73% of the stock is currently owned by institutional investors.

Remove Ads

Wave Life Sciences Stock Down 10.3 %

Shares of NASDAQ:WVE traded down $0.63 during midday trading on Thursday, hitting $5.51. The stock had a trading volume of 786,934 shares, compared to its average volume of 1,174,556. The company has a market cap of $845.09 million, a P/E ratio of -4.95 and a beta of -0.93. Wave Life Sciences Ltd. has a 12 month low of $4.25 and a 12 month high of $16.74. The business's 50-day simple moving average is $9.69 and its 200-day simple moving average is $11.70.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. As a group, equities analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now owns 16,115 shares in the company, valued at $157,443.55. This trade represents a 39.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on WVE. HC Wainwright reissued a "buy" rating and issued a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Jefferies Financial Group began coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 target price for the company. StockNews.com raised Wave Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Finally, Wedbush began coverage on shares of Wave Life Sciences in a report on Tuesday. They set an "outperform" rating and a $18.00 target price for the company. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $22.18.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.